Samedan Ltd Pharmaceutical Publishers


Advanced search

Publications European Pharmaceutical Contractor European Biopharmaceutical Review International Clinical Trials Pharmaceutical Manufacturing and Packing Sourcer Innovations in Pharmaceutical Technology Subscribe Online Conferences White Papers Samedan app Pharmaceutical Directory Industry Events Calendar News and Press Releases Employment Opportunities Advertising with us Contact Us

home > ebr > Winter 2013

PUBLICATIONS

European Biopharmaceutical Review

Winter 2013

Text

PDF

BioResearch and Innovation

Cell Based Therapies

Nobels and Stem Cells

The work of Sir John Gurdon and Shinya Yamanaka was recently awarded the Nobel Prize in Physiology or Medicine. Their groundbreaking work has led Dean Griffiths at Cambridge Consultants to investigate how a major discovery can start from a minor question.

Single-use Bioreactors

Rapid Reaction

Traditional stainless steel reactors are being overtaken by single-use bioreactors. Lee Madrid at EMD Millipore Corporation and Aurore Poles-Lahille at Millipore SAS outline the advantages that this new technology can bring.

Discovery Technology

Cloud Computing

Up, Up and Away

Inefficient data processing often stifles innovation in research and development. Richard Heitmann at Aspera discusses the vast possibilities to be gained in new medical advancements when modern technology is used to its full potential.

BioDevelopment

Sharing Data

Personal Medicine

In order to provide more bespoke therapeutics for cancer treatment, the industry needs to make a more conscious effort to collaborate and share patient data, says Markus Warmuth at H3 Biomedicine.

Drug Discovery

Stem Cell Technology

Treatment from Within

Distinguishing the correct cell types in liver cell transplantation is a vital factor that contributes substantially to the success of this therapy. Eric Halioua and Etienne Marc Sokal atPromethera Biosciences explore the advantages that intrahepatic cells have over other sources.

Differentiated Cells

iPS Power

The world of patient therapeutics can be drastically transformed through the use of in vitro differentiated cells that are derived from human induced pluripotent stem cells, Felix Haniel of Axiogenesis AG explains.

Safety Profile

A Marked Difference

Biomarkers are an invaluable tool in drug discovery and development. Federica Crivellente and Elena Vicentini at Aptuit suggest that the use of high throughput technologies can help to generate high quality data in a more efficient and cost-effective way.

Stem Cells in Drug Discovery

Patient in a Dish

Roberto Iacone at Roche and Blake Anson at Celluar Dynamics International examine how using improved induced pluripotent stem cell models will result in more effective medicines and help to overcome some of the challenges in this field.

BioRegional

Biosimilars: Asian Markets

Biotech in China

James C Greenwoodat Biotechnology Industry Organization assesses the growth of the Chinese biotech industry and how investment into new products could secure their position in the drug development and manufacturing market.

DEVELOPMENT AND PRODUCTION

Cell Line Development

Database Power

When trying to identify new cell lines, progress can be stifled by the data management process. If a more highly developed system were to be implemented, development timelines would decrease rapidly, as Eliot Randle at IDBS demonstrates.

Diabetes Therapeutics

Crackling the Code

A promising alternative for the treatment of type 1 diabetes has been discovered. Peter Hosking at Living Cell Technologies illustrates how using encapsulated porcine insulin-producing cells significantly reduces the number of hypoglycaemic events.

Published quarterly in

January, April,
July, and October

News and Press Releases

Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

OXFORD, UK and SAN JOSE, California, 13/06/2022 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen’s linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discovery platform. The companies will support these R&D efforts through joint funding and by combining their respective proprietary technologies.
More info >>

All releases >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

All white papers >>